AstraZeneca and Merck & Co’s Lynparza could offer a new option for certain patients with pancreatic cancer after a trial showed it slowed progression of the disease. Lynparza (olaparib) is a poly (ADP-ribose) polymerase, or PARP inhibitor class drug and is already established as a therapy for ovarian and breast cancer with BRCA mutations. The results add to the evidence that Lynparza and perhaps other PARP class drugs could work in other types of cancer that have the mutation, after ap...
READ MORE
|
New research showing that the first bacteria introduced into the gut have a lasting impact may one day allow scientists to adjust microbiomes the one-of-a-kind microbial communities that live in our gastrointestinal tracts to help ward off serious chronic diseases. Findings by U of A microbial ecologist Jens Walter and his colleagues suggest differences in our microbial makeup likely depend on when we acquire our first microorganisms after birth and the order they arrive in our gut has a lasting...
READ MORE
|
GlaxoSmithKline has been working to restrengthen in cancer, particularly through a multibillion-dollar purchase of Tesaro. The main drug from the buyout, Zejula, is now up for a priority review in late-stage ovarian cancer, where it's working to pick up a niche nod its rivals don't have. The FDA has accepted GSK's application for the drug to treat patients with advanced ovarian, fallopian tube or primary peritoneal cancer who have had at least three prior chemo regimens. The patients...
READ MORE
|
The government plans to review the existing drug price control measures to make medicines more affordable, while also undertaking "re-engineering" of price regulator NPPA to bring greater transparency amid allegations from the industry over arbitrary implementation of policy....
READ MORE
|
The European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) has announced its latest meeting highlights, including a restriction of the use of Xeljanz (tofacitinib), and a call for withdrawal of marketing authorisations for fenspiride medicines. The Xeljanz restriction comes as the organisation has started a new review of the drug, and has recommended, as a temporary measure during the review, that doctors must not prescribe the 10 mg twice-daily dose of this m...
READ MORE
|
NICE has approved Novartis’ CAR-T therapy Kymriah (tisagenlecleucel) for diffuse large B-cell lymphoma (DLBCL) in adults who did not respond to two or more previous treatments. The drug will be funded via the Cancer Drugs Fund (CDF) following a commercial agreement with NHS England. Kymriah was previously approved in England and Wales 2018 for paediatric and young adult patients up to 25 years of age with B-cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post-transp...
READ MORE
|